McKesson (NYSE:MCK) Releases FY 2025 Earnings Guidance

McKesson (NYSE:MCK - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 32.400-33.000 for the period, compared to the consensus EPS estimate of 31.990. The company issued revenue guidance of $355.3 billion-$361.5 billion, compared to the consensus revenue estimate of $351.8 billion.

McKesson Stock Down 0.6 %

Shares of MCK traded down $3.87 during trading hours on Friday, hitting $606.29. 1,003,998 shares of the company were exchanged, compared to its average volume of 824,784. McKesson has a fifty-two week low of $431.35 and a fifty-two week high of $637.51. The company has a market cap of $76.96 billion, a price-to-earnings ratio of 31.65, a P/E/G ratio of 1.35 and a beta of 0.44. The firm's fifty day moving average is $517.97 and its 200 day moving average is $553.80.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.88 by $0.19. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The firm had revenue of $93.65 billion for the quarter, compared to the consensus estimate of $89.33 billion. During the same period in the prior year, the company posted $6.23 earnings per share. The business's revenue for the quarter was up 21.3% on a year-over-year basis. Analysts anticipate that McKesson will post 32.81 EPS for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 2nd. Stockholders of record on Monday, December 2nd will be issued a $0.71 dividend. The ex-dividend date is Monday, December 2nd. This represents a $2.84 dividend on an annualized basis and a dividend yield of 0.47%. McKesson's dividend payout ratio (DPR) is currently 14.71%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Mizuho raised their target price on shares of McKesson from $540.00 to $570.00 and gave the company a "neutral" rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. raised their price objective on McKesson from $656.00 to $661.00 and gave the company an "overweight" rating in a report on Wednesday, August 21st. Baird R W raised McKesson from a "hold" rating to a "strong-buy" rating in a report on Thursday, November 7th. Citigroup lifted their price target on McKesson from $630.00 to $713.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Robert W. Baird upgraded McKesson from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $531.00 to $688.00 in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, McKesson has a consensus rating of "Moderate Buy" and a consensus target price of $631.57.

Insider Buying and Selling at McKesson

In related news, CEO Brian S. Tyler sold 3,753 shares of McKesson stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $561.10, for a total value of $2,105,808.30. Following the sale, the chief executive officer now owns 78,586 shares of the company's stock, valued at approximately $44,094,604.60. The trade was a 4.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.11% of the company's stock.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.